Endotoxins Standards and Their Role in Recovery Studies: The Path Forward
|
|
- Robert Horton
- 6 years ago
- Views:
Transcription
1 Endotoxins Standards and Their Role in Recovery Studies: The Path Forward The USP General Chapters Microbiology Expert Committee (EC) is the steward in the United States of harmonized Chapter <85>, Bacterial Endotoxins Test, or BET (USP 2016a). The EC has closely followed the Low Endotoxin Recovery ( LER ) discussion and publications since the interference was first described in 2013 (Chen and Vinther, 2013). It is important to note that the use of RSE and the BET for hold time studies is a non-compendial activity. However the concerns raised by some are important given the potential implications relative to the validity of the compendial BET assays for the release of LER products, and most importantly, patient safety. Summary The initial studies of the LER phenomenon describe a sudden and irreversible loss of endotoxin activity when Control Standard Endotoxin (CSE), in the form of chemically extracted and purified lipopolysaccharide (LPS) was added to an undiluted biological product containing a protein formulated in a chelating buffer with polysorbate. This observation led some readers, including some regulators, to assume that if the recovery of activity of this CSE is suppressed, then the activity of contaminating and native endotoxins must also be similarly affected. This assumption, made in the absence of supporting data, led some to an unsubstantiated conclusion that this loss of CSE activity equated to potential false negative LAL drug product release test results using <85>, a possible release of contaminated product into the marketplace, and therefore a possible patient safety concern. As a result, the United States Food and Drug Administration (FDA) has informed companies intending to submit new Biological License Applications (BLA) for an LER product that they must either demonstrate that they can overcome or correct for this interference seen with the CSE LPS in undiluted product or default to USP <151>, Pyrogen Test, also known as the Rabbit Pyrogen Test, to release product. The USP Expert Committee has proposed the concept of an alternate CSE preparation that we believe is a scientifically valid option as one possible resolution to this LER interference problem. Karen Zink McCullough MMI Associates Radhakrishna Tirumalai, Ph.D. United States Pharmacopeial Convention David Hussong, Ph.D. ValSource, LLC James Akers, Ph.D. Akers Kennedy Associates Dennis Guilfoyle, Ph.D. Johnson and Johnson Robert Mello, Ph.D. Mello PharmAssociates, LLC Donald Singer Glaxo Smith Kline Some Background In 2012, FDA retired a long standing Guidance document entitled, Guideline on Validation of the Limulus Amebocyte Lysate Test as an End-Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products, and Medical Devices (FDA, 1987), and replaced it with a new guidance document entitled, Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers (FDA, 2012). The genesis of the concept of a hold time as it relates to endotoxins recovery studies might be related to FDA s published concerns about holding product under inappropriate conditions and/or improper sample mixing prior to testing and release (Guilfoyle, et al, 1989). These concerns were ultimately published as Question 3 of the 2012 Questions and Answers document: Question 3: Is sample storage and handling important? Yes. The ability to detect endotoxins can be affected 14
2 by storage and handling. Firms should establish procedures for storing and handling (which includes product mixing) samples for bacterial endotoxins analysis using laboratory data that demonstrate the stability of assayable endotoxins content. Protocols should consider the source of endotoxins used in the study, bearing in mind that purified bacterial endotoxins might react differently from native sources of endotoxins. This seemingly simple question and its relatively short answer have precipitated a whole new set of questions related to storage and handling (i.e. hold time ) among Microbiologists in the parenteral industry: 1. What is hold time? a. Is hold time defined as FDA s original concern about endotoxins recovery between the completion of fill/finish activities (primary packaging) and testing? b. Is hold time a specified period of time that is built into the manufacturing process and described in the batch record to provide a required incubation or level of flexibility between processing steps? c. Is hold time essentially the entire process from the time that formulation takes place until the time that the product is tested or expires? d. Does hold time refer to conditions where the bulk is not sterile and where any Gram negative contamination could grow and produce endotoxins or does it also refer to hold times of sterile products where such proliferation and generation of endotoxins is not an issue? 2. What is stability? a. Is there a concern about the chemical or biochemical stability of contaminating endotoxin in a filled product? b. Is there a concern that contaminating endotoxin in a bulk product will somehow change, lose activity, and self depyrogenate? c. Is there a concern about LPS adsorbing to surfaces such as stoppers and vial walls that manifests as a loss of activity? 3. What are assayable endotoxins? 4. Is industry required to prospectively perform spiking studies to demonstrate the stability of activity during a hold time recovery study? November/December BioPharma Asia 15
3 5. If so, what spiking analyte is appropriate? a. Is the calibration standard (Reference Standard Endotoxin, or RSE) an appropriate surrogate for contaminating endotoxins? 6. What does the Guidance s disclaimer, Protocols should consider the source of endotoxins used in the study, bearing in mind that purified bacterial endotoxins might react differently from native sources of endotoxins mean? Discussions with a number of people who participated in the drafting of the 2012 Guidance (including three authors of this article) have provided some insight into the original intent of Question 3. The initial definition of hold time was meant to be the time between the completion of fill/finish and compendial release testing. Assayable endotoxins was meant to describe endotoxin activity in products that are naturally contaminated. Stability means that the activity of endotoxins in a naturally contaminated product can be recovered (within the error of the assay) throughout its defined storage period and conditions ( hold time ). And, yes, the authors did acknowledge that there could very well be a difference in the behavior of purified bacterial endotoxins (LPS reference standards) and native endotoxins in these hold time studies, suggesting that either a purified or a native analyte may be an appropriate spiking material. Laboratories and some regulators have interpreted the answer to Question 3 to mean that prospective spiking studies are expected to measure recovery of activity across study-specific parameters including time, temperature and sample container. Since there have been no public or published reports of any safety issues associated with LER, the focus of the discussion has now shifted from What is LER and is it relevant to patient safety? to Assuming such relevance, what is an appropriate analyte to use for these recovery studies? Should laboratories use purified LPS prepared in a manner similar to the RSE or is it scientifically justified to use native sources of endotoxins? Endotoxins Endotoxins are structural components of the Gram negative bacterial outer cell membrane. What makes the Gram negative outer membrane unique is the presence of lipopolysaccharide (LPS), an amphipathic molecule with a hydrophobic Lipid A end that is buried in the outer membrane of the bacterium, and a hydrophilic polysaccharide portion that extends beyond the outer membrane into the extracellular environment. The Lipid A part of the LPS molecule is the biologically active portion, which is recognized by immune cell receptors and can trigger a number of responses in mammals including fever (Pearson, 1985). Lipid A also initiates the Limulus Amebocyte Lysate (LAL) cascade. Although endotoxins activity is extremely rare in marketed pharmaceutical products, if a laboratory does find evidence of endotoxins, it is always the native form of the LPS molecule that is the contaminant; purified LPS cannot and does not contaminate pharmaceutical products because it does not exist in nature. Purified LPS is chemically extracted from Gram negative outer membranes in the laboratory. On the other hand native contaminants are vesicles (blebs, outer membrane vesicles/omv) that are naturally released from actively proliferating cells as part of the bacterial growth cycle, (Brogden and Phillips, 1988, Bonnington and Kuehn, 2016) as well as outer membrane fragments that are the result of disrupted cells. As an integral part of these vesicles and fragments, the LPS in native endotoxins is embedded in or associated with Gram negative outer membrane components including various proteins, phospholipids and lipoproteins (Brogden and Phillips, 1988, Bonnington and Kuehn, 2016). USP Endotoxin RS (RSE) USP Endotoxin RS (RSE) is the primary reference material used in the compendial BET tests <85>. The RSE is derived from E. coli strain 0113:H110K(-) (Rudbach, et al, 1976) that has been grown in a broth to produce a large quantity of native endotoxins. These native endotoxins are subsequently treated using the Westphal (hot phenol) extraction process to strip away the surrounding natural cell wall and outer membrane components. This preparation is further purified to produce bulk material for the RSE. This material, now commonly accepted and distributed by the World Health Organization, the United States Pharmacopeia, the European Pharmacopeia and the Japanese Pharmacopeia, is formulated in polyethylene glycol and lactose, components NOT associated with or found in native endotoxins. The current RSE is lyophilized, and each vial has an assigned activity 16
4 value of 10,000 endotoxin units (EU). (Poole, et al, 1997; Poole 2012). FDA s very first RSE was a Klebsiella pneumonia LPS preparation and Europe s first Biological Reference Preparation (BRP) was a liquid preparation of Salmonella abortus equii LPS. Why then was E. coli, an organism that is an unlikely contaminant in parenteral products, chosen as the source of the primary standard for the LAL test? It is important to understand that the current RSE was not chosen because it is worst case in terms of its relevance to the pharmaceutical industry, or the most difficult analyte to detect in a recovery study. Truth is, a number of early researchers looked at the relative potencies of LPS preparations from a range of Gram negative bacteria, and they generally found that E. coli LPS was typical in that it consistently had a mid-range potency (Rudbach, et al,1976; Firca and Rudbach, 1982; Weary and Pearson, 1982). The only thing special about this preparation is its history of use as a BET calibrant. As a typical LPS, it is no more or less representative to the pharmaceutical industry than endotoxins derived from other Gram negative species. It is also important to note that there is not a limitless supply of the current lot of RSE and a new standard supply will be required in the foreseeable future (Poole, et al, 2012). Secondary Standard: Control Standard Endotoxin The Control Standard Endotoxin (CSE) is, by definition, a secondary standard (USP, 1985). A definition of the CSE was provided in USP XXI: A Control Standard Endotoxin (CSE) is an endotoxin preparation other than the RSE that has been standardized against the RSE. If a CSE is a preparation not already adequately characterized, its evaluation should include characterizing parameters both for endotoxin quality and performance (such as reaction in the rabbit) and for suitability of the material to serve as a reference (such as uniformity and stability). By this definition, any preparation of bacterial endotoxins other than the RSE, regardless of source, can be called a CSE as long as it is characterized and standardized against the RSE. November/December 2016 BioPharma Asia 17
5 Although there is no requirement in this USP definition that a CSE must be either purified, formulated, lyophilized or of E. coli origin, all of the CSE preparations currently packaged in LAL test kits are, in fact, LPS extracted from various strains of E. coli. These preparations are further purified, most are further formulated, and all are lyophilized. Test kit CSEs are filled by weight (ng/ vial), not by activity (EU/mL or EU/vial). Standardization of these preparations requires the calculation of their specific activities relative to the RSE, meaning that the EU/ng must be experimentally determined. Lysate manufacturers provide this standardization service, and report potency in EU/ng that is referenced to a matched set of lysate lot and CSE lot, allowing, of course, for inherent biological assay variability. By contrast, a liquid CSE such as the original BRP has no potency because it has no determined weight. It is measured directly against the primary standard as a concentration of activity (EU/mL). Comparison: Table 1 compares the structure and properties of purified LPS and native endotoxins. For an excellent visual comparison in the form of electron micrographs of the two materials, see Brogden and Phillips (1988). LER, Control Standard Endotoxins, and Future Improvements The initial choice of a CSE analyte in the form of purified LPS for recovery studies from final dosage forms and product stream depyrogenation studies is understandable, as this material is readily available from lysate manufacturers, comes standardized and matched to a specific lot of lysate reagent, and is used for the Positive Product Control (PPC) in the compendial BET. However, studies by Bolden, Platco, Dubczak and their colleagues as well as other scientists using both purified LPS and native endotoxins as spiking analytes in their LER formulations have demonstrated that while activity of purified LPS is suppressed, the activity of native endotoxins may not be similarly suppressed. More importantly, rabbit pyrogen studies on LER formulations spiked with purified LPS or native endotoxins demonstrated that the LAL test correctly predicted rabbit febrile responses for all native endotoxins. In other words, when the LAL response to purified LPS was suppressed because of LER, so was the rabbit febrile response (Bolden, et al, 2015). What causes this suppression of activity in these LER product formulations? Because of their amphipathic nature, purified LPS molecules in aqueous solution tend to aggregate, forming micelles, ribbons, and other three-dimensional conformations. Data suggest that there is an optimal aggregation state for Purified LPS Native Endotoxins Biologically active portion is Lipid A that is stripped of its natural associated cell membrane components Extracted, usually by a hot phenol extraction (Westphal) and further purified. It is ultimately formulated with chemicals that are not native to the cell membrane, usually polyethylene glycol and a sugar, prior to lyophilization LPS molecules form aggregates in aqueous solution, with the extent of the aggregation dependent on the formulation of the matrix Readily adsorbs to surfaces Does not exist in nature and therefore cannot and does not contaminate parenteral products Biologically active portion is Lipid A existing in a natural state that is surrounded by components that are part of native Gram negative outer membrane. Exist as naturally generated and free floating outer membrane fragments and vesicles (blebs). LPS is embedded in or associated with cell membrane components (proteins, porin, phospholipids and lipoprotein). There is no extraction, no purification, and no further chemical formulation. Natives do not form aggregates in the same way as LPS since native LPS is embedded within cell membranes or vesicles Does not readily adsorb to surfaces Native endotoxins can be natural contaminants in water systems and raw materials, particularly those of natural origin. If not controlled, these natural contaminants can find their way into parenteral products. Table 1 18
6 a purified LPS to be biologically active. The citrate or phosphate buffer/polysorbate formulation that is common to LER products, chelates divalent cations and destabilizes these aggregates, which results in smaller aggregates or unreactive LPS monomers (Ribi, et al, 1966; Hannecart-Prokorni, et al, 1973; Gutsman, et al 2007; Tsuchiya, 2014). The biochemistry of the native endotoxins, their position in the cell membrane, and their ability to adapt to environments with low divalent cation concentrations (chelating formulations) make them much less susceptible to the inactivating effects of chelation (Bonnington and Keuhn, 2016). Chelating agents can also affect the lysate s ability to initiate and sustain the LAL cascade, so in this sense, chelating agents can adversely affect the recovery of both purified and native LPS. Referencing the data reported to date on the comparative recoveries of activity between native endotoxins and purified LPS in LER formulations and the correlation between loss of activity as measured by both the LAL test and the rabbit pyrogen test, the EC feels that it is scientifically valid to offer the laboratory a choice of a CSE in the form of native endotoxins. We recognize and understand the utility this new CSE or as an analyte in endotoxin activity recovery studies where the use of a native CSE more closely mimics a real life contamination event (USP 2016b; USP 2016c; Tirumalai, et al, 2016). It is important to note that this new offering will not replace either the current RSE as a primary calibration standard or the current CSEs as secondary standards. Rather, the proposed native CSE will provide an additional option for Microbiologists to use in their laboratory studies that is consistent with Question 13 from FDA s 2012 Guidance. Question 13: Are control standard endotoxins still acceptable for use in running bacterial endotoxins tests? Control standard endotoxins (CSEs) are endotoxin preparations other than the international or national reference standards that are traceable in their calibration to the international reference endotoxins standard. CSEs may be secondary or tertiary standards and are usually manufactured and certified by an LAL reagent manufacturer for use with a specific lot of reagent under defined assay conditions. CSEs have become an accepted source for preparation of standard curve calibrators and as assay controls, and have provided a cost saving to LAL users and helped to preserve the inventory of primary standards. FDA encourages the continued use of CSEs that are suitably calibrated to the international reference endotoxins standard. On 27 May 2016, The United States Pharmacopeia posted an Early Input notification seeking comments on a proposed Naturally Occurring Endotoxin (NOE) Reference Standard, which is, by definition, a CSE (USP 2016c). Early input is intended to gauge interest in the offering and understand any potential obstacles early on. This request for feedback outlined the proposed characteristics for the new CSE: To assure wide ranging availability and consistency, the CSE will be universally available in large quantities and distributed by USP. To assure consistency in manufacturing and testing, each lot of the native CSE will be accompanied by a Certificate of Analysis stating its activity in EU/mL as calibrated against the RSE. To reduce lot-to-lot variability, the material will be: o Prepared from a well characterized bacterial species that has been isolated from parenteral environments. o A member of the larger family of Enterobacteriaceae is consistent with this definition and is closely related to the current RSE standard, which is prepared from E. coli. o Manufactured under GMP conditions, meaning that it will have a batch record, will be subject to change control, and will have appropriate specifications that will be recorded on the Certificate of Analysis. The response to this request was overwhelmingly positive with 80% of respondents and experts in the field providing enthusiastic support for the Committee s proposal (Cooper, 2016). The Importance of Process Control Bacterial endotoxins don t spontaneously generate. Detecting endotoxins in any raw material, drug substance or drug product indicates that there were substantial numbers of proliferating Gram negative bacteria somewhere in the materials history. While the introduction of an alternate CSE in the form of native endotoxins may help companies to successfully execute recovery and product stream depyrogenation studies, by far the best strategy for assuring patient safety is one that identifies sources of potential contamination by endotoxins and works to control their introduction. 20
7 The good news is that because of increased focus on process control including control of water systems and raw materials that can be prime sources of Gram negative bacterial contamination, coupled with the appropriate use of the BET as a monitoring tool for the effectiveness of control measures, our industry experiences very few contaminated drug products that find their way into the marketplace. Summary The best way to safeguard patients against adverse reactions caused by bacterial endotoxins is clearly by controlling the quality of the inputs to the process and product and providing processing conditions that restrict the opportunity for microbial proliferation. The long history of improvements in process validation, statistical process control, control of bioburden, and the use of the BET as a tool to monitor the effectiveness of these control procedures have ensured the safety of parenteral products. Therefore, it is not surprising that there have been no reports of product pyrogenicity due to endotoxins with LER formulations, which have been in wide use since at least As evidenced by current data available in the public domain, the LER phenomenon is an issue related to the chosen analyte for a particular non-compendial recovery study rather than a concern with <85>, and therefore is neither a release testing nor patient safety issue. Unfortunately, the historical use of CSEs in the form of highly purified LPS has led to an assumption that these preparations must therefore also be the only or are the most appropriate surrogates for contaminating endotoxin when evaluating pharmaceutical processes and products. Since purified LPS is not and can never be a contaminant in parenteral products, the native CSE mirrors real life contamination in a way that chemically extracted and purified RSE and CSE cannot. The EC recognizes that the study of endotoxin contamination and its implications is a dynamic and complex one, and that the field changes as data are gathered. Information and feedback from the majority of the pharmaceutical/biopharmaceutical scientific community and experts studying endotoxins contamination suggest that broadening analyte options to include a well defined native CSE calibrated Related Product Focus - Hyglos November/December 2016 BioPharma Asia 21
8 against the RSE as long defined in the USP is not only a good scientific option, but is also an extremely pragmatic one. Literature Cited Bolden, J., C. Platco, J. Dubczak, J.F. Cooper, K.Z. McCullough The Use of Endotoxin as an Analyte in Biopharmaceutical Product Hold- Time Studies. Pharmacopeial Forum 41(5), Stimuli to the Revision Process Bonnington, K.E. and M. J. Kuehn Outer Membrane Vesicle Production Facilitates LPS Remodeling and Outer Membrane Maintenance in Salmonella during Environmental Transitions. mbio (5): e Brogden, K.A. and M. Phillips The Ultrastructural Morphology of Endotoxins and Lipopolysaccharides. Electron Microsc. Review. 1: Chen, J. and A. Vinther Low endotoxin recovery ( LER ) in common biologics products. Orlando: Parenteral Drug Association Annual Meeting; Cooper, James F Some Thoughts on USP s New NOE Standard. PDA Newsletter, 52(10). November/December. Firca, J. and J. A. Rudbach Reference Endotoxin: A Practical Rationale. In: Endotoxins and Their Detection with the Limulus Amebocyte Lysate Test. Stanley Watson, Jack Levin, Thomas Novitsky, editors. Alan R. Liss, New York Food and Drug Administration Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers guidancecomplianceregulatoryinformation/guidances/ucm htm Food and Drug Administration Guideline on Validation of the Limulus Amebocyte Lysate Test as an End-Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products, and Medical Devices (retired) Gutsmann, T., Andra, B. Schromm and K. Brandenburg The physicochemistry of endotoxins in relation to bioactivity. International J Medical Microbiology 297: Guilfoyle, D. E., J. F. Yager and S. L. Carito Effect of Refrigeration and Mixing on Detection of Endotoxin in Parenteral Drugs Using the Limulus Amebocyte Lysate (LAL) Test. J. Parent. Sci. Tech. 43(4): Hannecart-Porkorni, E., D. Dekegel, F. Depuydt Macromolecular Structure of Lipopolysaccharides from Gram-Negative Bacteria. Eur. J. Biochem. 38: 6-13 Pearson, F. C Endotoxin. In: Pyrogens: Endotoxins, LAL Testing, and Deyprogenation. Marcel Dekker, New York. Poole, S., P. Dawson, R.E, Gaines Das Second international standard for endotoxin: calibration in an international collaborative study. Related Product Focus - Charles River The revolutionary Endosafe -PTS cartridge technology is a proven UPS/EP compliant LAL testing method that provides realtime quantitative endotoxin analysis in 15 minutes. Licensed by the FDA in 2006 for in-process and final product release testing, the disposable pre-calibrated cartridges utilize LAL kinetic chromogenic methodology to measure color intensity directly related to the endotoxin concentration in a sample. Each cartridge contains precise amounts of licensed LAL reagent, chromogenic substrate, and control standard endotoxin (CSE) and are manufactured according to rigid quality control procedures to ensure test accuracy and product stability. Since there is no need to create a standard curve, positive product control or reconstitute LAL, a negative control is not needed, therefore eliminating preparation of multiple reagents and reducing the opportunity for technician error. By design, the PTS cartridge automatically performs a duplicate sample and positive product control LAL test, thereby satisfying the harmonized USP Bacterial Endotoxin Test for LAL testing. The Endosafe -PTS cartridges can be utilized with any of the highly flexible Endosafe rapid testing platforms to obtain results right at the point of sample collection, providing improved sample management, decreased testing time and accelerated product production. Discover how to streamline and simplify your endotoxin testing program at 22
9 J. Endotoxin Research. 4(3): Poole, S., T. Desai, L. Findlay, A. Heath, M. Crivellone, W. Hauck, M. Ambrose, T. Morris, E. Terao, J.M. Spieser, K.H. Buchelt, G. Rautman, A. Daas WHO International Standard for Endotoxin: Report of an International Collaborative Study to evaluate three preparations of endotoxin for their suitability to serve as the third international standard for bacterial endotoxin. WHO_BS_ _eng.pdf Ribi, E., R.L. Anacker, R. Brown, W.T. Haskins, B. Malbgren, K.C. Milner and J.A. Rudbach Reaction of Endotoxin and Surfactants. J. Bacteriol. 92(5): Rudbach, J. A., F.I. Akiya, R.J. Elin, H.D. Hochstein, M.K. Luoma, E.C.B. Milner, K.C. Milner, K.R> Thomas Preparation and Properties of a National Reference Endotoxin. J. Clin Microbiol. 3(1): Tirumalai, R., D. Hussong, J. Akers, K. McCullough USP Perspectives on LAL Assay Interference and NOE Standard. PDA Newsletter. 52(10). November/December Tsuchiya M. Possible mechanism of low endotoxin recovery. Am Pharm Rev. 2014;17(7): United States Pharmacopeia XXI <85>, Bacterial Endotoxins Test. United States Pharmacopeia. 2016a. <85>, Bacterial Endotoxins Test United States Pharmacopeia 2016b, second supplement. <1228.5>, Endotoxin Indicators United States Pharmacopeia. 2016c. Early Input, Proposed NOE Standard. Weary, M. and F. C. Pearson III The Activity of Various Endotoxins in the USP Rabbit Test and in Three Different LAL Assays. In: Endotoxins and Their Detection with the Limulus Amebocyte Lysate Test. Stanley Watson, Jack Levin, Thomas Novitsky, editors. Alan R. Liss, New York Joe Barco Director of Product Marketing Unchained Labs November/December 2016 BioPharma Asia 23
A RAPID KINETIC CHROMOGENIC METHOD FOR QUANTIFICATION OF BACTERIAL ENDOTOXINS IN LYOPHILIZED REAGENTS FOR LABELING WITH 99m Tc RADIOPHARMACEUTICALS
2009 International Nuclear Atlantic Conference - INAC 2009 Rio de Janeiro,RJ, Brazil, September27 to October 2, 2009 ASSOCIAÇÃO BRASILEIRA DE ENERGIA NUCLEAR - ABEN ISBN: 978-85-99141-03-8 A RAPID KINETIC
More informationChapter -2. Materials and Methods
Chapter -2 Materials and Methods 21 2.1 Validation of Bacterial Endotoxins Test Methods: Bacterial Endotoxins test (BET) method validation is used to document that a BET procedure will detect Endotoxin
More informationSensitive and flexible bacterial endotoxin testing with the EndoZyme II Recombinant Factor C Assay using the Synergy HTX Microplate Reader
217 Photo Ruder, Hyglos GmbH - a biomérieux company. Sensitive and flexible bacterial endotoxin testing with the EndoZyme II Recombinant Factor C Assay using the Synergy HTX Microplate Reader Rudolf Wedmann,
More informationBRIEFING 85 BACTERIAL ENDOTOXINS TEST. Portions of this general chapter have been harmonized with the corresponding texts of the European Pharmacopeia
11/1/016 116 USPC, Inc. 35(3) Harmonization Stage 6: 85 BACTERIAL ENDOTOXINS TEST BRIEFING 85 Bacterial Endotoxins Test, USP 3 page 93. The signed off PDG harmonization Stage 6 document is presented for
More informationResolving Test Interference in Detection of Endotoxin s in 3 rd Generation Cephalosporin Drug
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.2, No.2, pp 1286-1290, April-June 2010 Resolving Test Interference in Detection of Endotoxin s in 3 rd Generation Cephalosporin
More informationChanges in European Endotoxin Testing Regulations and Guidance By Mick Dawson
Testing Regulations and Guidance By Mick Dawson Associates of Cape Cod, Inc., East Falmouth, MA 02536 ~ 508.540.3444 ~ www.acciusa.com PR# 17-012 Introduction Between 2014 and 2016 the European Pharmacopoeia
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationV1.0 en 2017/02 EndoZyme II Recombinant Factor C Endotoxin Detection Assay
890030 200254 V1.0 en 2017/02 EndoZyme II Recombinant Factor C Endotoxin Detection Assay Fluorescence microplate assay using Recombinant Horseshoe Crab Factor C (rfc). Package Insert EndoZyme II Table
More informationPackage Insert EndoZyme
609050 606356 V2.0 en 2017/01 EndoZyme Recombinant Factor C Endotoxin Detection Assay Fluorescence microplate assay using Recombinant Horseshoe Crab Factor C (rfc). Package Insert EndoZyme Table of Contents
More informationPierce LAL Chromogenic Endotoxin Quantitation Kit
INSTRUCTIONS Pierce LAL Chromogenic Endotoxin Quantitation Kit 88282 Number Description 88282 Pierce LAL Chromogenic Endotoxin Quantitation Kit, sufficient reagents to perform 50 assays of standards and
More informationAseptic Sampling Best Practices Endotoxin Binding Affinity
Aseptic Sampling Best Practices Endotoxin Binding Affinity Scope Technical Note This technical report describes a study to evaluate binding affinity of Control Standard Endotoxin (CSE) to different plastic
More informationIN THIS SECTION MICROBIOLOGY TESTING EXPERT SOLUTIONS FOR PRODUCT DEVELOPMENT. Bacterial Endotoxin (LAL) Testing
EXPERT SOLUTIONS FOR PRODUCT DEVELOPMENT IN THIS SECTION MICROBIOLOGY TESTING Microbial assays involve a variety of tests, from the determination of the numbers and types of organisms naturally present
More informationEndotoxin Test Concerns of Biologics
Spike Recovery Endotoxin Test Concerns of Biologics Kevin L. Williams Hospira Inc. Limulus Amoebocyte Lysate (LAL) users are exploring regimens to study the effects of adding endotoxin to undiluted biologics
More informationEFFECT OF THE DILUTION FACTOR ON 18 FDG AND NA 18 F SAMPLES FOR BACTERIAL ENDOTOXIN TEST USING PTS
2011 International Nuclear Atlantic Conference - INAC 2011 Belo Horizonte,MG, Brazil, October 24-28, 2011 ASSOCIAÇÃO BRASILEIRA DE ENERGIA NUCLEAR - ABEN ISBN: 978-85-99141-04-5 EFFECT OF THE DILUTION
More informationMicrobiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical
Microbiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical RIGHT S O L U T I O N S RIGHT PARTNER Contents TGO 77 - Introduction Tests Performed
More informationHaemotox rfc. Package Insert. Article No.: For laboratory and research use only Not for use in diagnostic procedures
Package Insert Haemotox rfc Article No.: 31310 Storage: +2-8 C For laboratory and research use only Not for use in diagnostic procedures 1 Table of Contents 1 General Information 1.1. Intended Use 1.2.
More informationMicrobiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A
USP Antimicrobial Effectiveness Testing Microbiology Testing: Webinar Q&A 1. If a base ingredient is designed for the purpose of compounding a specific type of preparation does this forgo the necessity
More informationSterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)
Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE CriticalPoint s Sterile Compounding elearning curriculum is written by industry experts and covers both Chapter and
More informationComparison of Limulus Amebocyte Lysates and Correlation
APPLiED AND ENVIRONMENTAL MICROBIOLOGY, June 1977, p. 1265-1269 Copyright X) 1977 American Society for Microbiology Vol. 33, No. 6 Printed in U.S.A. Comparison of Limulus Amebocyte Lysates and Correlation
More informationGuidance for Industry
Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products Center for Drug Evaluation and Research (CDER) Center
More informationHaemotox rfc. Package Insert. Article No.: For laboratory and research use only Not for use in diagnostic procedures
Package Insert Haemotox rfc Article No.: 31210 Storage: +2-8 C For laboratory and research use only Not for use in diagnostic procedures 1 Table of Contents 1 General Information 1.1. Intended Use 1.2.
More informationCritical Environment Products and Services
Critical Environment Products and Services For over two decades, EP Scientific products and services have defined clean for environmental sampling containers and services. Our proprietary cleaning methods
More informationSterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)
Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE Fundamentals of Sterile Compounding (8 lessons/8 hours CE) The History of Compounding and USP Sterile Compounding Chapters
More informationWhy Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services
Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Disclosures I, Ross Caputo, declare no conflicts of interest, real or apparent, and
More informationIdentification and Control of Critical Process Points Using Complementary Risk Assessments (corrected)
Identification and Control of Critical Process Points Using Complementary Risk Assessments (corrected) Karen McCullough MMI Associates (908) 534-6463 PDA Metro Chapter Day June 2, 2009 RISK is a four letter
More informationHow Clean is Your BSA?
How Clean is Your BSA? Bovine serum albumin (BSA) is a critical component of many biotechnology and biochemistry systems. BSA is used in a variety of applications including diagnostics, veterinary medical
More informationExtending Beyond Use Dating for Compounded Preparations Webinar Q&A
Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific
More informationOverview 1.1 Product Reserve Technical Service LAL Training Sales Offices Information Ordering Courses History Option
www.acciusa.com Overview 1.1 History Ordering Information Sales Offices Product Reserve Option Technical Service LAL Training Courses History The Limulus Amebocyte Lysate (LAL) test was developed using
More informationExtending Beyond Use Dating for Compounded Preparations Webinar Q&A
Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific
More informationErin Patton, MS Senior Product Specialist Charles River Labs, Microbial Solutions
Validation of a Rapid Microbial Method Approach to Validation Case Studies: Equivalence Verification of an Alternate Assay for Microbial Limits Screening and Sterility Testing of Pharmaceutical Products
More informationLimulus Amebocyte Lysate (LAL) QCL-1000
Limulus Amebocyte Lysate (LAL) QCL-1000 Catalog Number: 50-647U TABLE OF CONTENTS TITLE PAGE Intended Use...................................................3 Warning.......................................................3
More informationThe New FDA Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers. LALUpdate
The New FDA Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers October, 2012 LALUpdate volume 28, number 1 Letter From The Editor On June 29, 2012 FDA released the long awaited
More informationWHO/BS/ and working document QAS/ ENGLISH ONLY
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 15 to 19 October 2012 EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS Amsterdam, 9-12 October 2012 WHO International
More informationá1225ñ VALIDATION OF COMPENDIAL PROCEDURES
1640 á1224ñ Transfer of Analytical Procedures / General Information USP 39 THE ANALYTICAL PROCEDURE The procedure should be written with sufficient detail and explicit instructions, so that a trained analyst
More informationLimulus Amebocyte Lysate (LAL) QCL-1000
Limulus Amebocyte Lysate (LAL) QCL-1000 Catalog Number: 50-647U, 50-648U BLANK TITLE TABLE OF CONTENTS PAGE Intended Use...................................................3 Warning.......................................................3
More informationPharma&Biotech. Translated versions available at
Pharma&Biotech β-g-blocker Translated versions available at www.lonza.com Content Section Page No. Intended Use Warning Explanation of Test 2 Principle 3 Reagents Supplied and Storage Conditions 3 Procedure
More informationGrowth Promotion Test Guide for Media Used in Sterility Tests
Growth Promotion Test Guide for Media Used in Sterility Tests The Sterility Test The purpose of the Sterility Test is to determine if a sample of a pharmaceutical product or component is sterile. A satisfactory
More informationThe Parenteral Drug Association
C O N F E R E N C E R E P O R T Equipment Cleaning Microbial Control Issues By Destin A. LeBlanc, M.A. Cleaning Validation Technologies Validation: The Parenteral Drug Association (PDA) spring conference
More informationLow Endotoxin Recovery (LER) Context and Resolution from a Broad Biologics Test Perspective
Pharma&Biotech Low Endotoxin Recovery (LER) Context and Resolution from a Broad Biologics Test Perspective Webinar: 20 and 21 October 2015 Speaker: Kevin L. Williams Senior Scientist for Endotoxin Detection,
More informationProposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823>
Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding Ravi Ravichandran, Ph.D. Steve Zigler, Ph.D. February 21, 2011 Agenda Rationale for the
More informationExcipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance
Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to
More informationCompounding Pharmacies and the USP <71> Sterility Tests
Compounding Pharmacies and the USP Sterility Tests Scott Sutton, Ph.D. scott.sutton@microbiol.org 49 41 Disclaimer I am making this presentation as an independent agent I am not making this presentation
More informationProduct Testing & Release. PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 10 th /11 th, 2007
Product Testing & Release PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 10 th /11 th, 2007 Product Testing Used to determine Safety, Purity, Identity, Potency, Quality Suitability
More informationAuditing Your Laboratory for Compliance with the FDA Dietary Supplement GMP s
Tech Tip 0020 With the advent of the cgmp s, the majority of companies are increasing the frequency of their outsourced analytical testing. But the GMPs are just that, Good Manufacturing Practices, and
More informationTechnical Manual No Version
ToxinSensor TM Chromogenic LAL Endotoxin Assay Kit Cat. No. L00350, L00350C Technical Manual No. 0354 Version 02062012 I Description.. 1 II Kit Contents.... 1 III Storage.... 2 IV Materials and equipment
More informationMicrobiological Cleaning Method Validation
Microbiological Cleaning Method Validation The purpose of cleaning procedures should never be to reduce bioburden to an acceptable level! Fergus O Connell QA Manager Eurofins ams Laboratories www.eurofins.com
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationDrug, Device and Diagnostic Manufacturing
Drug, Device and Diagnostic Manufacturing The Ultimate Resource Handbook Second Edition by Carol DeSain Table of Contents I. BIOMEDICAL RESEARCH AND DEVELOPMENT 1 A. Biomedical Research/Design 4 1. Identification
More informationEndotoxin Detection Systems. Systematic Approaches to Quantitative Methods
Systematic Approaches to Quantitative Methods Quantitative Endotoxin Detection Systems deliver accurate results up to a 4-log concentration range. Quantitative systems are amazingly easy to use: simply
More informationGUIDE TO INSPECTIONS OF MICROBIOLOGICAL PHARMACEUTICAL QUALITY CONTROL LABORATORIES
GUIDE TO INSPECTIONS OF MICROBIOLOGICAL PHARMACEUTICAL QUALITY CONTROL LABORATORIES Note: This document is reference material for investigators and other FDA personnel. The document does not bind FDA,
More informationA2LA. R231 Specific Requirements: Threat Agent Testing Laboratory Accreditation Program. December 6, 2017
Laboratory Page 1 of 17 Laboratory December 6, 2017 2017 by A2LA All rights reserved. No part of this document may be reproduced in any form or by any means without the prior written permission of A2LA.
More informationCustom processing services
Custom processing services Cleaning excellence for your critical environment The only thing in your container is what you add Save wasted resources dedicate your time to the manufacturing process, not
More informationSample Sizes in Uniformity Measurements The Role of USP
Sample Sizes in Uniformity Measurements The Role of USP Anthony J. DeStefano, Ph.D. Walter W. Hauck, Ph.D. Vice President, General Chapters Sr. Scientific Fellow US Pharmacopeia US Pharmacopeia Part I
More informationRecent USP Updates May, 2013
Recent USP Updates May, 2013 Don Singer GSK Bioburden Control of Non-sterile Drug Substances and Products The chapter emphasizes control as a risk mitigation strategy The chapter recommends a risk-based
More informationThe Bacterial Endotoxins Test:
The Bacterial Endotoxins Test: A Practical Approach PDA Bethesda, MD, USA DHI Publishing, LLC River Grove, IL, USA 10 987654321 ISBN: 1-933722-49-5 Copyright 2011 All rights reserved. All rights reserved.
More informationNew General Chapter on Host Cell Protein Assays (2.6.34)
European Pharmacopoeia Training Session on Biologicals 7-8 February 2017, Strasbourg New General Chapter on Host Cell Protein Assays (2.6.34) Gwenael Cirefice Scientific Officer, European Pharmacopeia
More informationAt Your ServIce. Microbiology Services. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.
At Your ServIce Microbiology Services The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. Microbiology Services Optimize your QC lab workflow and ensure regulatory compliance
More informationPharma&Biotech. Limulus Amebocyte Lysate (LAL) PYROGENT U.S. Licence No Translated versions available at
Pharma&Biotech Limulus Amebocyte Lysate (LAL) PYROGENT -5000 U.S. Licence No. 1775. Translated versions available at www.lonza.com Content Section Page No. 1 Intended Use 2 1 Warning 2 1 Explanation of
More informationMicrobial Quality. of the latter have been reviewed and discussed. are abundant in the gastrointestinal tract, and
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Nov. 1979, p. 885-890 0099-2240/79/11-0885/06$2.00/0 Vol. 38, No. 5 Determining Endotoxin Content of Ground Beef by the Limulus Amoebocyte Lysate Test as a Rapid
More informationBiotechnology Industry Organization 1225 Eye Street NW, Suite 400 Washington, DC 20006
Biotechnology Industry Organization 1225 Eye Street NW, Suite 400 Washington, DC 20006 December 4, 2003 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville,
More informationLIMULUS AMEBOCYTE LYSATE PYROGENT Catalog No. N383, N384 License No. 709
LIMULUS AMEBOCYTE LYSATE PYROGENT -5000 Catalog No. N383, N384 License No. 709 LIMULUS AMEBOCYTE LYSATE PYROGENT -5000 License No. 709 Catalog No. N383, N384 IMPORTANT Read Entire Brochure Before Performing
More informationValidation of Sterilizing Grade Filters
Validation of Sterilizing Grade Filters Presented by Laura Okhio-Seaman Sartorius Corporation 1 Sterilizing Grade Filters The definition of a sterilizing grade filter is one that will produce a sterile
More informationEZ-CFU Microorganisms
EZ-CFU Microorganisms The EZ-CFU Microorganism preparations provide quantitative challenges for mandated Pharmacopeial applications. INTENDED USE EZ-CFU Microorganisms are lyophilized, quantitative microorganism
More informationINSTRUCTIONS FOR USE
INSTRUCTIONS FOR USE EZ-Accu Shot Microorganisms EZ-Accu Shot Select Microorganisms INTENDED USE EZ-Accu Shot and EZ-Accu Shot Select microorganisms are lyophilized, enumerated microorganism preparations
More informationChanges to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodi
Changes to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodies Office of Biotechnology Products Center for Drug
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationStudy Summary. Results: All tested media-filled vials were negative for growth of any microorganisms.
A 7 Days Microbial Ingress Test of Single Use Vials Utilizing the EQUASHIELD Closed System Drug Transfer Device Study by Nelson Laboratories (Salt Lake City, UT) 2013, updated in 2014* Study Summary Abstract:
More informationINSTRUCTIONS FOR USE
INSTRUCTIONS FOR USE Epower Microorganisms INTENDED USE Epower microorganisms are lyophilized, quantitative microorganism preparations to be used in industrial laboratories for quality control purposes.
More informationQuality is Our Promise.
Quality is Our Promise. Our goal at KRS Global Biotechnology is to provide the highest quality pharmaceutical preparations. We accomplish this with an unrivaled quality assurance and quality control program
More informationPublished papers 143
Published papers 143 1 st Paper Name: Sorting out of interference in detection of Endotoxins in biotherapeutic drugs Journal: Indian journal of science and technology 144 Indian Journal of Science and
More informationISO INTERNATIONAL STANDARD. Water for haemodialysis and related therapies. Eau pour hémodialyse et thérapies apparentées
INTERNATIONAL STANDARD ISO 13959 Second edition 2009-04-15 Water for haemodialysis and related therapies Eau pour hémodialyse et thérapies apparentées Reference number ISO 13959:2009(E) ISO 2009 ISO 13959:2009(E)
More informationThe Application of Pharmaceutical cgmp to Live Bacterial Products. James Harris Business Development Manager
The Application of Pharmaceutical cgmp to Live Bacterial Products James Harris Business Development Manager The Objective CMC expectations of a cgmp live bacterial biopharmaceutical project Overview Define
More informationMethod Validation Studies How GLP Interacts With Guidance Documents
Method Validation Studies How GLP Interacts With Guidance Documents Steven S. Kuwahara ROBERT GEORGE YOUNG/GETTY IMAGES GLP Forum addresses topics of interest associated with good laboratory practices.
More informationSOP: LFA SOP For Bacterial Endotoxin (LAL) Test
SOP For Bacterial Endotoxin (LAL) Test Alastair Sanderson 31/08/16 1 Objective Procedure to follow to perform Bacterial Endotoxin (LAL) test for detection of endotoxin in materials to be tested 2 Scope
More informationHandbook of Microbiological Quality Control
Handbook of Microbiological Quality Control Pharmaceuticals and Medical Devices Edited by ROSAMUND M. BAIRD Department of Pharmacy and Pharmacology, University of Bath, UK NORMAN A. HODGES School of Pharmacy
More informationA highly sensitive assay for endotoxin detection and quantitation for a variety of sample types
WHITE AER ierce Chromogenic Quant Kit A highly sensitive assay for endotoxin detection and quantitation for a variety of sample types contamination is a common problem with recombinant proteins and nucleic
More informationQuality risk management and the economics of implementing rapid microbiological methods
Quality risk management and the economics of implementing rapid microbiological methods Quality risk management (QRM) is an important part of science-based decision making which is essential for the quality
More informationPreparing the CMC section of IMPD for biological/biotechnology derived substances
Preparing the CMC section of IMPD for biological/biotechnology derived substances Your Logo Dr. Una Moore Health Products Regulatory Authority, Ireland Presented by Una Moore on 16 th April 2014. Health
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE- GENERAL Health systems and products Medicinal products quality, safety and efficacy 18 February 2010 EMA/CHMP/BWP/534898/2008 Committee for Medicinal
More informationHow to Select a Microbiology Contract Testing Laboratory? Tony Cundell, Ph. D. Microbiological Consulting, LLC Scarsdale, New York
How to Select a Microbiology Contract Testing Laboratory? Tony Cundell, Ph. D. Microbiological Consulting, LLC Scarsdale, New York June 13, 2017 IVT Microbiology Week 1 Presentation Overview Rationale
More informationCatalog Number: N190. Certificate of Analysis at
β-g-blocker Catalog Number: N190 Certificate of Analysis at www.lonza.com/coa BLANK β-g-blocker Cat. No. N190 INTENDED USE ß-G-Blocker is intended as an adjunct for the In Vitro end-product endotoxin testing
More informationPerspectives on Method Validation: Importance of Adequate Method Validation
Perspectives on Method Validation: Importance of Adequate Method Validation Heather Bridwell, Vikas Dhingra, Daniel Peckman, Jennifer Roark and Thomas Lehman The appropriate validation of analytical methods
More informationA24 CALA Checklist for Microbiology Revision 4.1 February 16, 2018
A24 CALA Checklist for Microbiology Revision 4.1 February 16, 2018 Laboratory Name: Appendix Name: Appendix Number: Assessor: Date: Rev. 4.1 CALA CHECKLIST FOR MICROBIOLOGY Item 01 SAMPLING AND SAMPLE
More informationUSP <1223> Revision and the Alternative Microbiological Methods Workshop Tony Cundell, Ph. D. Consulting Microbiologist, Scarsdale, New York, USA
USP Revision and the Alternative Microbiological Methods Workshop Tony Cundell, Ph. D. Consulting Microbiologist, Scarsdale, New York, USA September, 2015 biomerieux Meeting 1 Presentation Outline
More informationGood practices in quality control in pharmaceutical industry - Overview of regulatory guidelines
Review Article Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Chagi Venkatesh*, S. B. Puranik ABSTRACT Good practices in quality control (QC) department
More informationProducing a Pharmaceutical or Biopharmaceutical. The Manufacturing Process
Producing a Pharmaceutical or Biopharmaceutical The Manufacturing Process Process development Scientists and engineers begin to figure out how to scale up production of a drug even before it receives FDA
More informationPackage Insert. EndoLISA. EndoLISA. Cat. No tests. Store the kit at 2 to 8 C
EndoLISA Endotoxin Detection Assay based on ELISA-technology Fluorescence microplate assay using a phage-derived capture molecule and a recombinant Factor C derived from horseshoe crab Package Insert EndoLISA
More informationRisk Assessments for Host Cell Protein Control Strategies: CDER Experiences
Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences Laurie Graham FDA/CDER Office of Pharmaceutical Quality (OPQ) Office of Policy for Pharmaceutical Quality (OPPQ) 1 Disclaimer
More informationEvaluating Novel Methods for Endotoxin Testing of Cellular Products The PACT Experience
Evaluating Novel Methods for Endotoxin Testing of Cellular Products The PACT Experience Diane Kadidlo Operations Manager University of Minnesota Molecular and Cellular Therapeutics Facility Objectives
More informationEffect of ph on Turbidity and Ultrastructures of Endotoxins Extracted from Salmonella minnesota Wild Type and Re Mutant
Microbiol. I mmunol. Vol. 29 (1), 75-80, 1985 Effect of ph on Turbidity and Ultrastructures of Endotoxins Extracted from Salmonella minnesota Wild Type and Re Mutant Ken-ichi AMANO, Toshinobu SATO, and
More informationPharmaceutical Reference Standards: Overview and Role in Global Harmonization
Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference
More informationMethod validation is the process used to confirm that
Developing a Validation Strategy for Rapid Microbiological Methods Michael J. Miller, Ph.D. President, Microbiology Consultants, LLC All analytical methods need to be validated prior to their introduction
More informationINSTRUCTIONS FOR USE. EZ-CFU One Step Microorganisms INTENDED USE FORMULA COMPONENTS
INSTRUCTIONS FOR USE EZ-CFU One Step Microorganisms INTENDED USE EZ-CFU One Step microorganisms are lyophilized, enumerated microorganism preparations to be used in industrial laboratories for quality
More informationSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
More informationBest Practices For Cleaning Validation in the Aseptic Environment SUMMARY OF OUTLINE
Best Practices For Cleaning Validation in the Aseptic Environment Vivienne Yankah, PhD, CQE sanofi pasteur Ltd. Toronto, Canada SUMMARY OF OUTLINE Review Regulatory Standards for CV Designing and Developing
More informationPDA: A Global. Association. Matrix Approach to Media Fills. (c) 2012 Catalent Pharma Solutions. All rights reserved.
PDA: A Global Matrix Approach to Media Fills Association (c) 2012 Catalent Pharma Solutions. All rights reserved. Overview Guidance Overview Matrix Introduction Why Matrix Media Fills Sample Matrix New
More information2018 EDITORIAL COVERAGE. Connecting the Pharma Industry for 28 Years.
2018 EDITORIAL COVERAGE Connecting the Pharma Industry for 28 Years EDITORIAL COVERAGE: EXPERT INSIGHT AND ANALYSIS Pharmaceutical Technology Europe sets the standard for publishing independent, industry-leading
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationPyroGene Recombinant Factor C Endotoxin Detection System
PyroGene Recombinant Factor C Endotoxin Detection System Catalog Number: 50-658U, 50-658NV BLANK TITLE TABLE OF CONTENTS PAGE Intended Use...................................................3 Warning.......................................................3
More information